 Effectiveness imazodan treatment chronic congestive heart failure Imazodan Research Group multicenter double-blind placebo-controlled trial imazodan type III phosphodiesterase inhibitor patients congestive heart failure clinical efficacy safety Patients mg imazodan Patients standard therapy diuretics digoxin angiotensin-converting enzyme inhibitor mean ejection fraction Exercise time baseline groups significant difference placebo group treated groups regard time ejection fraction frequency ventricular premature complexes ventricular tachycardia intent placebo mortality imazodan mortality significant study imazodan benefit exercise performance placebo